Latest news

Nature Cancer, August 2021.

Lucile Vanhersecke, Maxime Brunet, Jean-Philippe Guégan, Christophe Rey, Antoine Bougouin, Sophie Cousin, Sylvestre Le Moulec, Benjamin Besse, Yohann Loriot, Mathieu Larroquette, Isabelle Soubeyran, Maud Toulmonde, Guilhem Roubaud, Simon Pernot, Mathilde Cabart, François Chomy, Corentin Lefevre, Kevin Bourcier, Michèle Kind, Ilenia Giglioli, Catherine Sautès-Fridman, Valérie Velasco, Félicie Courgeon, Ezoglin Oflazoglu, Ariel Savina, Aurélien Marabelle, Jean-Charles Soria, Carine Bellera, Casimir Sofeu, Alban Bessede, Wolf H. Fridman, François Le Loarer & Antoine Italiano.

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
Annals of Oncology, 2021, Aug. 18.

Using a syngeneic MCA205 sarcoma tumor model – widely used for the evaluation of innovative cancer immunotherapies – we investigated the anti-tumor activity of several combination therapies. This model is known to be responsive to PD1/PDL1 axis blockade but only partially to anti-CTLA4 antibody. Interestingly, while an additive benefit of anti-PD1 and anti-PDL1 is observed, a clear synergistic effect is achieved upon combination of either anti-PD1 or anti-PDL1 with anti-CTLA4, with a full tumor rejection in all treated animals.

Clinical Cancer Research, April 2021

Cousin S, Cantarel C, Guegan JP, Gomez-Roca C, Metges JP, Adenis A, Pernot S, Bellera C, Kind M, Auzanneau C, Le Loarer F, Soubeyran I, Bessede A, Italiano A.

Take advantage of new available seats on board or our upcoming shuttle session, scheduled by early May, to cost-effectively run your candidates on our robust M2 macrophage polarization assaythereby saving up to 25% full cost.

Digital pathology for tumor immune infiltrate analysis and patient selection
To assess whether or not the tumor immune contexture was predictive of response to the Avelumab-Regorafenib combination regimen, Explicyte developed and ran, on baseline FFPE samples, a multiplexed immunohistofluorescence panel consisting of CD8, PD1, PDL1, CD163, IDO1, and PanKeratin markers, in addition to Dapi (Discovery XT, Roche Diagnostics).

Explicyte is planning a new cost-effective in vivo shuttle session by end of February and thus provides an opportunity to speed up your new cancer therapy discovery process.

It therefore becomes primordial to benefit from a technological platform that allows to deal with the tumor biology complexity/heterogeneity and get specific investigations in compartments of interest (e.g. tumor vs stroma). Thanks to the GeoMx platform (Nanostring Inc.), which combines the spatial resolution of immunohistofluorescence with the high-plex gene/protein expression analysis, the Digital Spatial Profiling (DSP) revolution has started.

We have fully set up and characterized a syngeneic Renca renal mouse model recapitulating most of the human RCC condition features. Indeed, our model displays an enriched tumor microvascular environment and relatively low immune infiltration - nevertheless constituted of a strong Myeloid-Derived Suppressor Cells (MDSCs) proportion.

To deal with the current challenge of a qualitative and quantitative tumor immune landscape characterization, we have set up a fully integrated platform spanning from FFPE slide preparation and staining, to image digitization and analysis.